
- /
- Supported exchanges
- / US
- / BLUE.NASDAQ
Bluebird bio Inc (BLUE NASDAQ) stock market data APIs
Bluebird bio Inc Financial Data Overview
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Bluebird bio Inc data using free add-ons & libraries
Get Bluebird bio Inc Fundamental Data
Bluebird bio Inc Fundamental data includes:
- Net Revenue: 104 M
- EBITDA: -149 196 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -4.635
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bluebird bio Inc News

Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions
Stockholders that have previously tendered their shares must re-tender their shares Stockholders may elect to receive either $3.00 per share plus CVR of $6.84 per share in cash payable upon achieveme...


Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity
Bluebird Bio, Inc. (NASDAQ:BLUE) shares are trading higher on Wednesday following the news that Bluebird Bio, Carlyle, and SK Capital Partners, LP, have amended their definitive agreement. Under the ...

Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement
Stockholders may elect to receive either $3.00 per share plus CVR of $6.84 per share in cash payable upon achievement of a net sales milestone or $5.00 per share with no CVR SOMERVILLE, Mass., May 14...

Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio
bluebird Board of Directors unanimously supports the transaction as the only viable option for stockholders to receive consideration for their shares and recommends that all stockholders immediately t...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.